Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Will there be any positive news this year?
View:
Post by JackRedwood on Sep 08, 2021 10:15am

Will there be any positive news this year?

Will this stock ever reach over 30 cents? I bought at 22 and want to sell before the year is over.
Comment by M101 on Sep 08, 2021 11:48am
Top Broker says "September is going to be a huge month", so just put on your ruby slippers and tap your heels together 3 times. 
Comment by DavidKingCanada on Sep 08, 2021 12:52pm
Top Broker seems very optimistic! Hopefully they are correct! Imo, buy and hold for now. Wait 2-5 Years. Lots of potential. It might hit 30 cents but thats not enough for most Investors.
Comment by Thenorth1990 on Sep 08, 2021 6:42pm
- pending pr on serology , hopefully we don't have to wait until March 2022 to know. - long silence about all other programs , so some update will be nice including ad vaccine which was announced last year September. Not sure how sp is going to be boosted, we need double the volume considering the dilution. However 30 cents isn't too far, a good pr can probably get us there.. atleast for 1 ...more  
Comment by JackRedwood on Sep 08, 2021 9:36pm
Thanks for the info! looking PROMISing ;)
Comment by retiredcop on Sep 09, 2021 10:49am
The ad vaccine is at least a year away 
Comment by Thenorth1990 on Sep 09, 2021 2:51pm
May be even longer RC, I am looking more for some update on the progress so far. This has been an year where the pr have been mostly about appointments and funding
Comment by farmerjane on Sep 09, 2021 8:40pm
Cashman said last year in podcast 7 years to get into clinic for AD vaccine
Comment by JackRedwood on Sep 09, 2021 9:16pm
I also think we should wait 3-5 years atleast for things to get better. 
Comment by G1945V on Sep 10, 2021 8:29am
ProMis needs to get rolling with the Phase 1 Clinical trial for things to start heading in the right direction ASAP and stop with its delay! jmo G1945V
Comment by BottomBroker on Sep 10, 2021 12:50pm
Phase I sounds like it's a least a year off. It's the possibility of a partnership (which could happen at any time) that's keeping things interesting right now, IMO.
Comment by Speyeder999 on Sep 10, 2021 10:19am
Farmer J, went back to listen to the podcast cause I didn't recall any mention of 7 yerars, but you may have interpereted ''several years'' as ''seven years''. Still a long wait, but a little more encouraging :-) GLTA
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities